Zero Gravity Solutions, Inc. Stocks

$ 0.9Last Updated 20.03.2025

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

$ 35.82M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.9
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zero Gravity Solutions, Inc., an agricultural biotechnology company, focuses on the commercialization of technology derived from and designed for long term spaceflight and planetary colonization with applications to agriculture on earth. The company offers BAM-FX, an ionic nutrient delivery platform for food crops that deliver minerals and micronutrients systemically at the cellular level of a plant; and Directed Selection, which relates to the production and alteration of various novel stem cells with characteristics in the prolonged zero/micro gravity environment of the International Space Station. It patents its stem cells for commercial sale to third parties. The company was formerly known as ElectroHealing Technologies, Inc. and changed its name to Zero Gravity Solutions, Inc. in January 2013. Zero Gravity Solutions, Inc. was founded in 1983 and is headquartered in Boca Raton, Florida.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks